BHV-4157

PreclinicalSmall molecule

BBiohaven Therapeutics Ltd.

BHV-4157 is one of 13 small molecule programs targeting Cerebellar Ataxia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebellar AtaxiaActive, not recruiting

Cerebellar AtaxiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Cerebellar Ataxia

#DrugCompanyPhaseTrials

Fampridine

Biogen

Phase 3

1 2

Rilutek

AAzurity Pharmaceuticals

Phase 2

3 3

Lithobid

SSolvay Pharmaceuticals

Phase 2

2 4

Tasigna

AAzurity Pharmaceuticals

Phase 2

1 5

Asceniv

CSL Behring

Phase 1

1 6

Ivig

Argenx

Phase 2

1 7

SLS-005

SSeelos Therapeutics, Inc.

Phase 3

1 8

Stemchymal

SSteminent Biotherapeutics Inc.

Phase 2

2 9

CAD-1883

CCadent Therapeutics

Phase 2

1 10

Ampyra

MMerz Pharmaceuticals GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Trial1 trial

Open Pilot Trial of BHV-4157

Active, not recruiting·UUniversity of California, Los Angeles·Phase 3·NCT03408080·24 enrolled

Cerebellar Ataxia1 trial

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Active, not recruiting·BBiohaven Therapeutics Ltd.··NCT06529146·909 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BHV-4157. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BHV-4157 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BHV-4157. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biohaven Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBiohaven Therapeutics Ltd.

BHV-4157

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Trial1 trial

Cerebellar Ataxia1 trial

References

Drug Info

Quick Facts

Related News